IC-Green

Manufacturer
Akorn
Effective date
2022-09-12
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
13
Source
legacy-cache
Hydrated at
2026-08-01 21:53:56

Label at a glance#

ProductIC-Green
Active ingredientindocyanine green
Label structure17 sections

Indications and uses

IC-GREEN ® is indicated:

Dosage and administration

In the performance of dye dilution curves, a known amount of dye is injected as a single bolus as rapidly as possible via a cardiac catheter into selected sites in the vascular system. A recording instrument (oximeter or densitometer) is attached to a needle or catheter for sampling of the dye-blood mixture from a systemic arterial sampling site. Under sterile conditions, the IC-GREEN ® powder should be dissolved ...

Storage and handling

IC-GREEN ® is supplied in a kit (NDC 17478-701-02) containing six 25 mg IC-GREEN ® vials and six 10 mL Sterile Water for Injection, USP ampules: NDC 17478-701-25 IC-GREEN ® vial. 25 mg fill in 20 mL vial. NDC 17478-701-10 Sterile Water for Injection, USP ampule. 10 mL fill in 10 mL ampule. Each combination of IC-Green vial and Sterile Water for Injection ampule is intended for single-patient-use. STORAGE: Store at...

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

IC-GREEN® is indicated:

1.1 For Determining Cardiac Output, Hepatic Function and Liver Blood Flow

SPL UNCLASSIFIED SECTION

1.2 For Ophthalmic Angiography

SPL UNCLASSIFIED SECTION

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

2.1 Indicator-Dilution Studies

SPL UNCLASSIFIED SECTION

In the performance of dye dilution curves, a known amount of dye is injected as a single bolus as rapidly as possible via a cardiac catheter into selected sites in the vascular system. A recording instrument (oximeter or densitometer) is attached to a needle or catheter for sampling of the dye-blood mixture from a systemic arterial sampling site.

Under sterile conditions, the IC-GREEN® powder should be dissolved with the Sterile Water for Injection, USP provided for this product, and the solution used within 6 hours after it is prepared. If a precipitate is present, discard the solution.

The usual doses of IC-GREEN® for dilution curves are as follows:

Adults - 5.0 mg

Children - 2.5 mg

Infants - 1.25 mg

These doses of the dye are usually injected in 1 mL volume. An average of five dilution curves are recommended in the performance of a diagnostic cardiac catheterization. The total dose of dye injected should be kept below 2 mg/kg.

While sterile water for injection may be used to rinse the syringe, isotonic saline should be used to flush the residual dye from the cardiac catheter into the circulation so as to avoid hemolysis. With the exception of the rinsing of the dye injection syringe, saline should be used in all other parts of the catheterization procedure.

Calibrating Dye Curves: To quantitate the dilution curves, standard dilutions of IC-GREEN® in whole blood are made as follows. It is strongly recommended that the same dye that was used for the injections be used in the preparation of these standard dilutions. The most concentrated dye solution is made by accurately diluting 1 mL of the 5 mg/mL dye with 7 mL of distilled water. This concentration is then successively halved by diluting 4 mL of the previous concentration with 4 mL of distilled water.

If a 2.5 mg/mL concentration was used for the dilution curves, 1 mL of the 2.5 mg/mL dye is added to 3 mL of distilled water to make the most concentrated “standard” solution. This concentration is then successively halved by diluting 2 mL of the previous concentration with 2 mL of distilled water.

Then 0.2 mL portions (accurately measured from a calibrated syringe) of these dye solutions are added to 5 mL aliquots of the subject's blood, giving final concentrations of the dye in blood beginning with 24.0 mg/liter, approximately (actual concentration depends on the exact volume of dye added). This concentration is, of course, successively halved in the succeeding aliquots of the subject's blood. These aliquots of blood containing known amounts of dye, as well as a blank sample to which 0.2 mL of saline containing no dye has been added, are then passed through the detecting instrument and a calibration curve is constructed from the deflections recorded.

2.2 Hepatic Function Studies

SPL UNCLASSIFIED SECTION

Due to its absorption spectrum, changing concentrations of IC-GREEN® (indocyanine green for injection) in the blood can be monitored by ear densitometry or by obtaining blood specimens at timed intervals. The technique for both methods is as follows.

The patient should be studied in a fasting, basal state. The patient should be weighed and the dosage calculated on the basis of 0.5 mg/kg of body weight.

Under sterile conditions, the IC-GREEN® powder should be dissolved with the Sterile Water for Injection, USP provided. Exactly 5 mL of Sterile Water for Injection, USP should be added to the 25 mg vial giving 5 mg of dye per mL of solution.

Inject the calculated amount of dye (0.5 mg/kg of body weight) into the lumen of an arm vein as rapidly as possible, without allowing the dye to escape outside the vein. (If the photometric method is used, prior to injecting IC-GREEN ® , withdraw 6 mL of venous blood from the patient's arm for serum blank and standard curve construction, and through the same needle, inject the correct amount of dye.)

Ear Densitometry: Ear oximetry has also been used and makes it possible to monitor the appearance and disappearance of IC-GREEN® without the necessity of withdrawal and spectrophotometric analysis of blood samples for calibration. An ear densitometer which has a compensatory photo-electric cell to correct for changes in blood volume and hematocrit, and a detection photo cell which registers levels should be used. This device permits simultaneous measurement of cardiac output, blood volume and hepatic clearance of IC-GREEN®*. This technique has been employed in newborn infants, healthy adults and in children and adults with liver disease. The normal subject has a removal rate of 18 to 24% per minute. Due to the absence of extra-hepatic removal, IC-GREEN® was found to be suited for serial study of severe chronic liver disease and to provide a stable measurement of hepatic blood flow. In larger doses, IC-GREEN® can be used in detecting drug-induced alterations of hepatic function and in the detection of mild liver injury.

Using the ear densitometer, a dosage of 0.5 mg/kg in normal subjects gives the following clearance pattern.

Figure
Figure
Figure
Figure

*Dichromatic earpiece densitometer supplied by The Waters Company, Rochester, Minnesota.

SPL UNCLASSIFIED SECTION

Photometric Method -

SPL UNCLASSIFIED SECTION

Determination Using Percentage Retention of Dye:

A typical curve obtained by plotting dye concentration versus optical density is shown. The percent retention can be read from this plot. If more accurate results are desired, a curve using the patient's blood and the vial of IC-GREEN® being used in the determination can be constructed as follows:

  1. Take 6 mL of non-dye-containing venous blood from the patient's arm. Place in a test tube and allow the blood to clot. The serum should be separated by centrifugation.
  2. Pipette 1 mL of the serum into a microcuvette.
  3. Add 1 lambda (λ) of the 5 mg/mL aqueous IC-GREEN® (sterile indocyanine green) solution to the serum, giving a dilution of 5 mg/liter, the standard for 50% retention. (The addition of 2 lambda (λ) of the 5 mg/mL IC-GREEN® solution would give 100% retention; however, this concentration cannot be read on the spectrophotometer.)
  4. The optical density of this solution should be read at 805 nm, using normal serum as the blank.
  5. Using graph paper similar to that used in the illustration, plot the 50% figure obtained in Step 4, and draw a line connecting this point with the zero coordinates.
SPL UNCLASSIFIED SECTION

Percentage Retention: A single 20-minute sample (withdrawn from a vein in the opposite arm to that injected) should be collected and allowed to clot, centrifuged and its optical density determined at 805 nm using the patient's normal serum as the blank. The dye concentration can be read from the curve above. A single 20-minute sample of serum in healthy subjects should contain no more than 4% of the initial concentration of the dye. The use of percentage retention is less accurate than percentage disappearance rate. Hemolysis is not expected to interfere with a reading.

SPL UNCLASSIFIED SECTION

Determination Using Disappearance Rate of Dye: To calculate the percentage disappearance rate, obtain samples at 5, 10, 15 and 20 minutes after injecting the dye. Prepare the sample as in the previous section and measure the optical densities at 805 nm, using the patient's normal serum as the blank. The IC-GREEN® concentration in each timed specimen should be determined by using the concentration curve illustrated. Values should be plotted on semilogarithmic paper.

Specimens containing IC-GREEN® should be read at the same temperature since its optical density is influenced by temperature variations.

Normal Values: Percentage disappearance rate in healthy subjects is 18 to 24% per minute. Normal biological half-time is 2.5 to 3.0 minutes.

2.3 Ophthalmic Angiography Studies

SPL UNCLASSIFIED SECTION

The excitation and emission spectra (Figure 1) and the absorption spectra (Figure 2) of IC-GREEN® make it useful in ophthalmic angiography.

Figure 1
Figure 1
Figure 2
Figure 2

Dosages up to 40 mg IC-GREEN® dye in 2 mL of Sterile Water for Injection, USP should be used, depending on the imaging equipment and technique used. The antecubital vein can be injected with an IC-GREEN® dye bolus and should immediately be followed by a 5 mL bolus of normal saline.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

IC-GREEN® is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide.

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

IC-GREEN® contains sodium iodide and should be used with caution in patients who have a history of allergy to iodides because of the risk of anaphylaxis.

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Anaphylaxis

SPL UNCLASSIFIED SECTION

Deaths from anaphylaxis have been reported following IC-GREEN® administration during cardiac catheterization.

5.2 Drug Instability

SPL UNCLASSIFIED SECTION

IC-GREEN® is unstable in aqueous solution and must be used within 6 hours. However, the dye is stable in plasma and whole blood so that samples obtained in discontinuous sampling techniques may be read hours later. Sterile techniques should be used in handling the dye solution as well as in the performance of the dilution curves. If a precipitate is present, discard the solution.

5.3 Drug/Laboratory Test Interactions

DRUG & OR LABORATORY TEST INTERACTIONS SECTION

Radioactive iodine uptake studies should not be performed for at least a week following the use of IC-GREEN®.

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Anaphylactic or urticarial reactions have been reported in patients with or without history of allergy to iodides. If such reactions occur, treat with the appropriate agents, e.g., epinephrine, antihistamines, and corticosteroids.

7 DRUG INTERACTIONS

DRUG INTERACTIONS SECTION

Preparations containing sodium bisulfite, including some heparin products reduce the absorption peak of IC-GREEN® in blood and, therefore, should not be used as an anticoagulant for the collection of samples for analysis.

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Animal reproduction studies have not been conducted with IC-GREEN®. It is also not known whether IC-GREEN® can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. IC-GREEN® should be given to a pregnant woman only if clearly indicated.

8.3 Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when IC-GREEN® is administered to a nursing woman.

8.4 Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients have been established. See DOSAGE AND ADMINISTRATION (2) for specific dosing information in pediatric patients.

8.5 Geriatric Use

GERIATRIC USE SECTION

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

10 OVERDOSAGE

OVERDOSAGE SECTION

There are no data available describing the signs, symptoms, or laboratory findings accompanying overdosage. The LD50 after intravenous administration ranges between 60 and 80 mg/kg in mice, 50 and 70 mg/kg in rats and 50 and 80 mg/kg in rabbits. Based on body surface area, these doses are 2.4 to 13-fold the maximum recommended human (MRHD) dose of 2 mg/kg for indicator-dilution studies, 10 to 52-fold the MRHD of 0.5 mg/kg for hepatic-function studies, and 7 to 39-fold the MRHD of 0.67 mg/kg for ophthalmic angiography studies.

11 DESCRIPTION

DESCRIPTION SECTION

IC-GREEN® is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide and sodium hydroxide to adjust the pH to 6.2. It is packaged with Sterile Water for Injection, USP used to dissolve the indocyanine green. IC-GREEN® is to be administered intravenously.

Indocyanine green is a water soluble, tricarbocyanine dye with a peak spectral absorption at 800 nm. The chemical name for Indocyanine Green is 1 H-Benz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4-sulfobutyl)-2H-benz[e] indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-,hydroxide, inner salt, sodium salt. IC-GREEN® has a pH of approximately 6.5 when reconstituted. Each vial of IC-GREEN® contains 25 mg of indocyanine green as a sterile lyophilized powder.

Structural Formula
Structural Formula

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

IC-GREEN® permits recording of the indicator-dilution curves for both diagnostic and research purposes independently of fluctuations in oxygen saturation. Following intravenous injection, IC-GREEN® is rapidly bound to plasma protein, of which albumin is the principle carrier (95%). IC-GREEN® undergoes no significant extrahepatic or enterohepatic circulation; simultaneous arterial and venous blood estimations have shown negligible renal, peripheral, lung or cerebro-spinal uptake of the dye. IC-GREEN® is taken up from the plasma almost exclusively by the hepatic parenchymal cells and is secreted entirely into the bile. After biliary obstruction, the dye appears in the hepatic lymph, independently of the bile, suggesting that the biliary mucosa is sufficiently intact to prevent diffusion of the dye, though allowing diffusion of bilirubin. These characteristics make IC-GREEN® a helpful index of hepatic function.

The peak absorption and emission of IC-GREEN® lie in a region (800 to 850 nm) where transmission of energy by the pigment epithelium is more efficient than in the region of visible light energy. IC-GREEN® also has the property of being nearly 98% bound to blood protein, and therefore, excessive dye extravasation does not take place in the highly fenestrated choroidal vasculature. It is, therefore, useful in both absorption and fluorescence infrared angiography of the choroidal vasculature when using appropriate filters and film in a fundus camera.

The plasma fractional disappearance rate at the recommended 0.5 mg/kg dose has been reported to be significantly greater in women than in men, although there was no significant difference in the calculated value for clearance.

13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No studies have been performed to evaluate the carcinogenicity, mutagenicity, or impairment of fertility.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

IC-GREEN® is supplied in a kit (NDC 17478-701-02) containing six 25 mg IC-GREEN® vials and six 10 mL Sterile Water for Injection, USP ampules:

NDC 17478-701-25 IC-GREEN® vial. 25 mg fill in 20 mL vial.

NDC 17478-701-10 Sterile Water for Injection, USP ampule. 10 mL fill in 10 mL ampule.

Each combination of IC-Green vial and Sterile Water for Injection ampule is intended for single-patient-use.

STORAGE AND HANDLING SECTION

STORAGE: Store at 20° to 25°C (68° to 77°F).

AKORN

Manufactured by: Akorn
Lake Forest, IL 60045
IG00N     Rev. 09/21

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Principal Display Panel Text for Container Label:

NDC 17478-701-25

IC-GREEN®

(indocyanine green

for injection, USP)

25 mg Sterile Rx only

single-patient-use

Principal Display Panel Text for Container Label
Principal Display Panel Text for Container Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Principal Display Panel Text for Carton Label:

Akorn Logo NDC 17478-701-02

IC-GREEN®

(indocyanine green

for injection, USP)

25 mg kit

Sterile Rx only

Principal Display Panel Text for Carton Label
Principal Display Panel Text for Carton Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Principal Display Panel Text for Container Label:

NDC 17478-701-10

Sterile Water

for Injection, USP

for IC-GREEN® (indocyanine

green for injection, USP)

10 mL Sterile Rx only

single-patient-use

Principal Display Panel Text for Container Label
Principal Display Panel Text for Container Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Principal Display Panel Text for Carton Label:

NDC 17478-701-10

Akorn Logo

Sterile Water

for Injection, USP

for IC-GREEN®

(indocyanine green

for injection, USP)

Sterile

6 Ampules

(10 mL each) Rx only

Principal Display Panel Text for Carton Label
Principal Display Panel Text for Carton Label

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
17478-701-02EA - Each17478-7011a9a22a9-a395-447e-9b51-579b8b23d78612012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
indocyanine greenACTIVE INGREDIENTIX6J1063HV5
indocyanine green acid formACTIVE MOIETYC4V974V9325
WaterINACTIVE INGREDIENT059QF0KO0R5

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 5 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
17478-70117478-701-02

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 3 matching rows.

Name, UNII, Kind table
NameUNIIKind
indocyanine greenIX6J1063HVACTIB
Water059QF0KO0RIACT
Water059QF0KO0RIACT

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 4 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N011525-001IC-GREENINDOCYANINE GREEN25MG/VIALINJECTABLE / INJECTIONAPRLD, Approved before 1982
N011525-002IC-GREENINDOCYANINE GREEN50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 1982
N011525-003IC-GREENINDOCYANINE GREEN10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONRS, Approved before 1982
N011525-004IC-GREENINDOCYANINE GREEN40MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 1982

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
N011525-001AP

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 5 · 172 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08N011525-001IC-GREEN25MG/VIALINJECTABLE / INJECTIONAPRLD, Approved before 198284e616aacf4f…
2026-09-14 22:38:342026-08N011525-002IC-GREEN50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 198284e616aacf4f…
2026-09-14 22:38:342026-08N011525-003IC-GREEN10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONRS, Approved before 198284e616aacf4f…
2026-09-14 22:38:342026-08N011525-004IC-GREEN40MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 198284e616aacf4f…
2026-08-18 06:07:402026-07N011525-001IC-GREEN25MG/VIALINJECTABLE / INJECTIONAPRLD, Approved before 1982caaa826d4ba7…
2026-08-18 06:07:402026-07N011525-002IC-GREEN50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 1982caaa826d4ba7…
2026-08-18 06:07:402026-07N011525-003IC-GREEN10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONRS, Approved before 1982caaa826d4ba7…
2026-08-18 06:07:402026-07N011525-004IC-GREEN40MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 1982caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N011525-001IC-GREEN25MG/VIALINJECTABLE / INJECTIONAPRLD, Approved before 1982011fe1cb6892…
2026-02-19 14:30 UTC2026-02N011525-002IC-GREEN50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 1982011fe1cb6892…
2026-02-19 14:30 UTC2026-02N011525-003IC-GREEN10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 1982011fe1cb6892…
2026-02-19 14:30 UTC2026-02N011525-004IC-GREEN40MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 1982011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N011525-001IC-GREEN25MG/VIALINJECTABLE / INJECTIONAPRLD, Approved before 198231067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N011525-002IC-GREEN50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 198231067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N011525-003IC-GREEN10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 198231067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N011525-004IC-GREEN40MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 198231067a03dcf5…
2025-08-23 18:47 UTC2025-08N011525-001IC-GREEN25MG/VIALINJECTABLE / INJECTIONAPRLD, Approved before 19826a471c1ec25d…
2025-08-23 18:47 UTC2025-08N011525-002IC-GREEN50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 19826a471c1ec25d…
2025-08-23 18:47 UTC2025-08N011525-003IC-GREEN10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 19826a471c1ec25d…
2025-08-23 18:47 UTC2025-08N011525-004IC-GREEN40MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 19826a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N011525-001IC-GREEN25MG/VIALINJECTABLE / INJECTIONRLD, Approved before 1982fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N011525-002IC-GREEN50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 1982fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N011525-003IC-GREEN10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 1982fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N011525-004IC-GREEN40MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 1982fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N011525-001IC-GREEN25MG/VIALINJECTABLE / INJECTIONRLD, Approved before 1982b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N011525-002IC-GREEN50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 1982b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N011525-003IC-GREEN10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 1982b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N011525-004IC-GREEN40MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 1982b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N011525-001IC-GREEN25MG/VIALINJECTABLE / INJECTIONRLD, Approved before 198203ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N011525-002IC-GREEN50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 198203ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N011525-003IC-GREEN10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 198203ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N011525-004IC-GREEN40MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 198203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N011525-001IC-GREEN25MG/VIALINJECTABLE / INJECTIONRLD, Approved before 19822680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N011525-002IC-GREEN50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 19822680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N011525-003IC-GREEN10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 19822680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N011525-004IC-GREEN40MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 19822680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N011525-001IC-GREEN25MG/VIALINJECTABLE / INJECTIONRLD, Approved before 19825bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N011525-002IC-GREEN50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 19825bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N011525-003IC-GREEN10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 19825bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N011525-004IC-GREEN40MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**INJECTABLE / INJECTIONApproved before 19825bbf6a4d5a75…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08N011525-001AP184e616aacf4f…
2026-08-18 06:07:402026-07N011525-001AP1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N011525-001AP1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N011525-001AP131067a03dcf5…
2025-08-23 18:47 UTC2025-08N011525-001AP16a471c1ec25d…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N011525-001AP15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N011525-001AP15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N011525-001AP14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N011525-001AP174a2ff9319b5…
2022-03-09 01:35 UTC2022-03N011525-001AP1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N011525-001AP1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N011525-001AP187673890dc5c…
2021-03-12 10:30 UTC2021-03N011525-001AP15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N011525-001AP18869cabd3fbd…
2020-11-12 02:37 UTC2020-11N011525-001AP1c0c555d07b60…
2019-12-14 00:12 UTC2019-12N011525-001AP13f01610625f2…
2019-09-15 20:21 UTC2019-09N011525-001AP1b00525d2431f…
2019-07-19 19:46 UTC2019-07N011525-001AP1ea99ee380514…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N011525-001AP1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N011525-001AP13f0d92c62455…
2023-05-13 08:27 UTC2023-05N011525-001AP1053a50430f4f…
2023-01-26 05:58 UTC2023-01N011525-001AP13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N011525-001AP13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N011525-001AP1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09N011525-001AP1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07N011525-001AP1cb3db0bc1861…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N011525-001AP1a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
b6698ece-d732-433b-bbb2-193f308f9a53fe138b13-43e1-4ab2-8882-07ed91bb70ea2023-10-03Warnings, Adverse reactionsExact identifier
spl set id: fe138b13-43e1-4ab2-8882-07ed91bb70ea

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.